Skip Nav

Clinical Guidelines Portal

Home > Guidelines > Pediatric ARV Guidelines > Protease Inhibitors (PIs)
Text Size

Updated Pediatric ARV Guidelines

Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection were released on Thursday, November 1, 2012. Please send your comments to ContactUs@aidsinfo.nih.gov by November 15, 2012.

Corrections were made to the guideline. For a description of the changes, please see the correction notice.

Search Search Help

Guideline Search

Type your search term(s) in the text box. Users can only search one guideline at a time. To search for an exact phrase, use quotation marks (i.e. "what to start"). To narrow your search, add additional relevant terms. If you are not finding what you need, try searching similar terms (i.e. perinatal OR pregnancy) to broaden your search.Close

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Appendix A: Pediatric Antiretroviral Drug Information

Protease Inhibitors (PIs)

Printer-Friendly Files

Atazanavir (ATV, Reyataz) 
 Darunavir (DRV, Prezista) 
 Fosamprenavir (FPV, Lexiva) 
 Indinavir (IDV, Crixivan) 
 Lopinavir/Ritonavir (LPV/r, Kaletra) 
 Nelfinavir (NFV, Viracept) 
 Ritonavir (RTV, Norvir) 
 Saquinavir (SQV, Invirase) 
 Tipranavir (TPV, Aptivus)